Latest news

Versant launches Dayra with $50M Biogen deal to chase oral macrocyclic peptide drugs

Versant launches Dayra with $50M Biogen deal to chase oral macrocyclic peptide drugs

Eduardo Longoria
Daily Snap - 24. November 2025

Daily Snap - 24. November 2025

Joachim Eeckhout
Contineum’s multiple sclerosis drug fails phase 2 test, raising doubts on its potential

Contineum’s multiple sclerosis drug fails phase 2 test, raising doubts on its potential

Eduardo Longoria
Daily Snap - 21. November 2025

Daily Snap - 21. November 2025

Joachim Eeckhout
Aspen secures $115M to advance its Parkinson’s research and a pivotal trial

Aspen secures $115M to advance its Parkinson’s research and a pivotal trial

Eduardo Longoria
Pfizer's mRNA flu shot outperforms Sanofi’s Fluzone by 34.5% in late-stage trial

Pfizer's mRNA flu shot outperforms Sanofi’s Fluzone by 34.5% in late-stage trial

Eduardo Longoria
Daily Snap - 20. November 2025

Daily Snap - 20. November 2025

Joachim Eeckhout
Merck’s HIV drug rivals Gilead’s blockbuster in key trial

Merck’s HIV drug rivals Gilead’s blockbuster in key trial

Eduardo Longoria
Arrowhead wins first FDA approval, igniting biotech rivalry with Ionis

Arrowhead wins first FDA approval, igniting biotech rivalry with Ionis

Eduardo Longoria
Daily Snap - 19. November 2025

Daily Snap - 19. November 2025

Joachim Eeckhout
Roche’s breast cancer pill hits key goal and becomes leader in the oral SERD race

Roche’s breast cancer pill hits key goal and becomes leader in the oral SERD race

Eduardo Longoria
Zymeworks pivots to royalty-first model after cancer drug success

Zymeworks pivots to royalty-first model after cancer drug success

Eduardo Longoria
FirstBack
12345678
Next Last